MARKET

XXII

XXII

22ND CENTURY
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6279
+0.0628
+11.11%
After Hours: 0.6425 +0.0146 +2.33% 19:35 09/25 EDT
OPEN
0.5900
PREV CLOSE
0.5651
HIGH
0.6660
LOW
0.5800
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
2.460
52 WEEK LOW
0.5500
MARKET CAP
87.19M
P/E (TTM)
-3.2151
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
22nd Century Group Provides Strategy Update Letter from CEO
GlobeNewswire · 1d ago
22nd Century CEO Sends Letter To Shareholders
Dear Fellow Shareholders, When I first spoke with you during our 2020 second quarter earnings call, I had been CEO of 22nd Century for only three weeks and was still evaluating the strategic ambition, opportunities, and
Benzinga · 1d ago
Health Check: How Prudently Does 22nd Century Group (NYSEMKT:XXII) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 3d ago
22nd Century Appoints Leading Plant Biotechnology Expert Dr. Michael Koganov to Board of Directors
Dr. Koganov to Leverage his Pharmaceutical, Consumer Packaged Goods, and Life Science Expertise as Chair of 22nd Century’s Scientific and Technical Advisory Committee Dr. Michael Koganov 22nd Century Appoints Leading Plant Biotechnology Expert Dr. Michael Koganov to Board of DirectorsWILLIAMSVILLE,
GlobeNewswire · 09/17 20:05
LD Micro: 360 Companies Set to Present this Week
ACCESSWIRE · 08/31 23:05
22nd Century Group to Present at the LD Micro 500 Virtual Conference
WILLIAMSVILLE, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based life science company driven by next generation plant biotechnology, today announced that the Company’s executive management team will present
GlobeNewswire · 08/27 16:30
22nd Century Group, Inc. (XXII) CEO Jim Mish on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/06 14:47
22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020
GlobeNewswire · 08/06 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XXII. Analyze the recent business situations of 22ND CENTURY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XXII stock price target is 11.50 with a high estimate of 11.50 and a low estimate of 11.50.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 35.63M
% Owned: 25.66%
Shares Outstanding: 138.85M
TypeInstitutionsShares
Increased
26
1.15M
New
10
11.16M
Decreased
24
726.16K
Sold Out
14
345.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Environmental Services & Equipment
+1.87%
Professional & Commercial Services
+1.88%
Key Executives
Chairman/Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer
James Mish
Chief Financial Officer
John Franzino
Vice President
John Brodfuehrer
Vice President
Lisa Parks
Vice President - Research & Development
Juan Tamburrino
Director of Investor Relations
Mei Kuo
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XXII
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of 22nd Century Group Inc stock information, including AMEX:XXII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XXII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XXII stock methods without spending real money on the virtual paper trading platform.